View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Georg Tigalonov-Bjerke
  • Morten Larsen
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Georg Tigalonov-Bjerke
  • Morten Larsen
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Georg Tigalonov-Bjerke
  • Morten Larsen
ABGSC Healthcare Research ... (+4)
  • ABGSC Healthcare Research
  • Alexander Krämer
  • Georg Tigalonov-Bjerke
  • Morten Larsen
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Alexander Krämer
  • Morten Larsen
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Alexander Krämer
  • Morten Larsen
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Alexander Krämer
  • Morten Larsen
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Alexander Krämer
  • Morten Larsen
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Alexander Krämer
  • Morten Larsen
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Alexander Krämer
  • Morten Larsen
ABGSC Healthcare Research ... (+3)
  • ABGSC Healthcare Research
  • Alexander Krämer
  • Morten Larsen
Adam Karlsson ... (+3)
  • Adam Karlsson
  • Gonzalo Artiach
  • Morten Larsen

FluoGuide - Q3 report: advancing at the right pace

No material updates in Q3 report Brain, lung an H&N Ph 2 trials ongoing, readouts in H1’23e Expect a neutral share price reaction

Adam Karlsson ... (+3)
  • Adam Karlsson
  • Gonzalo Artiach
  • Morten Larsen

FluoGuide - Positive interim data in lung cancer trial

FG001 lighted up lung cancer in 5 out of 7 patients Optimal dose and time of administration to be established We expect the share to trade up ~10% today

Adam Karlsson ... (+4)
  • Adam Karlsson
  • Erik Cassel
  • Jakob Lembke
  • Morten Larsen

FluoGuide - Q2’22 report

No material updates in the report Cash and cash equivalents at DKK 39m Multiple readouts expected during 2023

Adam Karlsson ... (+4)
  • Adam Karlsson
  • Erik Cassel
  • Jakob Lembke
  • Morten Larsen

FluoGuide - Q1’22 report

FG001 is progressing according to plan DKK 50m in cash & better cost control Report neutral for share – attractive risk/reward

Adam Karlsson ... (+4)
  • Adam Karlsson
  • Erik Cassel
  • Jakob Lembke
  • Morten Larsen

FluoGuide - New confirmatory data in HGG

Lights up in 11/11 new patients & confirmatory histology Enables it to proceed with phase 2 component… ... enabling potential efficacy readout in Q3’22e

Adam Karlsson ... (+4)
  • Adam Karlsson
  • Erik Cassel
  • Jakob Lembke
  • Morten Larsen

FluoGuide - FY’2021 results

Clinical programs developing according to plan DKK 64m in cash after share issue, 4Q cash runway Neutral share price reaction warranted

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch